Schizophrenia, treating

Travis, M. J., Busatto, G. F., Pilowsky, L. S. et al. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br. J.Psychiatr. 173 236-241, 1998. [Pg.959]

Bender, L. (1947) One hundred cases of childhood schizophrenia treated with electric shock. Trans Am Neurol Soc 72 165—169. Caracci, G. and Decina, P. (1991) Fluoxetine and prolonged seizure. Convulsive Ther 7 145—147. [Pg.384]

TABLE 5-24. Assessment of outcome in patients with schizophrenia treated with and without antipsychotic drugs and psychotherapy... [Pg.80]

Benaton R, Sirota P, Megged S. Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Convuls Thet 1996 12 117-121. [Pg.98]

The effects of neuroleptic drugs on menstrual status and the relation between menstrual status and neuroleptic drug efficacy and adverse effects have been explored (744). In contrast to prior reports (SEDA-18, 50), there was not a high prevalence of menstrual irregularities or amenorrhea in 27 premenopausal women with chronic schizophrenia treated with typical neuroleptic drugs. [Pg.624]

Additionally, three other epidemiological studies have identified a higher risk of diabetes associated with olanzapine (Sernyak 777,778). The first of these studies included out-patients with schizophrenia treated over 4 months in 1999 (Sernyak 561). When patients who had taken atypical drugs (n = 22 648) were compared with... [Pg.626]

Bergemann N, Mundt C, Parzer P, Jannakos I Nagl I, Salbach B, Klinga K, Runnebaum B, Resch F. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 2005 73 357-66. [Pg.679]

Bobes J, Rejas J, Garcfa-Garcla M, Rico-Villademoros F, Garcfa-Portilla MP, Fernandez I, Hernandez G, for the EIRE Study Group. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol results of the EIRE study. Schizophr Res 2003 62 77-88. [Pg.680]

Lindenmayer J-P, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003 160 290-6. [Pg.680]

Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents. Arch Gen Psychiatry 2005 62 19-28. [Pg.680]

Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, Dickson RA. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002 63(5) 408-13. [Pg.686]

Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, et al. 2006. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 81 291-300. [Pg.312]

Szulc A, Galinska B, Tarasow E, Kubas B, Dzienis W, et al. 2007. N-acetylaspartate (naa) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics A proton magnetic resonance spectroscopy (lh mrs) study. Med Sci Monit 13 Suppl 1 17-22. [Pg.440]

The correlation between plasma clozapine concentration and heart rate variability has been studied in 40 patients with schizophrenia treated with clozapine 50-600 mg/day (31). The patients had reduced heart rate variability parameters, which correlated negatively with plasma clozapine concentration. [Pg.264]

A 55-year-old man with a 15-year history of schizophrenia treated with various neuroleptic drugs developed a tremor and was given tetrabenazine 75 mg/day, with complete regression of the tremor. Three months later he developed depression, a known adverse effect of tetrabenazine, which was discontinued, with subsequent partial improvement of his depressive symptoms but reappearance of the tardive tremor. Clozapine 25 mg/day was started and increased to 75 mg/day his tardive tremor again disappeared. [Pg.268]

Mamo D, Kapur S, Shammi C, Papatheodorou G, Mann S, Therrien F, Remington G. A pet study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004 161 818-25. [Pg.372]

Cocaine has been associated with movement disorders, such as acute dystonias, choreoathetosis, and akathisia. Chronic pancerebellar dysfunction occurred in a cocaine user with schizophrenia treated with risperidone (129). [Pg.500]

Richardson AJ, Easton T, Puri BK. Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. Eur Neuropyschophaimacol 2000 10 189-193. [Pg.355]

The annuahzed relapse rate for patients with chronic schizophrenia treated with haloperidol decanoate 50 and 100 mg per month is 75%. [Pg.177]

A prolonged period of increased motor activity after starting reserpine ( reserpine-reversal ) possibly occurred in 3 patients with schizophrenia treated firstly with phenelzine for 12 weeks, then a placebo for 16 to 33 weeks, and lastly reserpine for 12 weeks, when compared with patients receiving reserpine who had not received an MAOI. Their blood pressures rose slightly and persistently, and their psychomotor activity was considerably increased, lasting in two cases throughout the 12-week period of treatment. ... [Pg.1142]

Cardiovascular Cardiovascular disease mortahty in patients with chronic schizophrenia treated with cloz ine has been retrospectively assessed [71 ]. Patients with schizophrenia who started to take clozapine ( = 1084) were compared with patients who took risperidone and had never taken clozapine ( = 602). During the follow-up period of 6-10 years 43 deaths were attributed to cardiovascular disease. There was no difference in cardiovascular mortality in patients aged under 55 years at the start of treatment (clozapine 1.1% and 2.7% versus risperidone 1.0% and 2.8% at 5 years and 10 years respectively). Patients who started treatment at an age of at least 55 years had higher cardiovascular mortality... [Pg.63]

Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, Wanen KR, Conley RR. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine a retrospective cohort study. J Clin Psychiatry 2010 71 304-11. [Pg.80]

Corya SA. Post-injection delirium/seda-tion syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I analysis of cases. BMC Psychiatry 2010 10 43. [Pg.83]

The role of CYP2D6 and ABCBl pharmacogenetics in drug-naive patients with first-episode schizophrenia treated with risperidone. Eur J Qin Pharmacol 2010 66 1109-17. [Pg.84]

Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, Hall GC, Le Jeunne C, Mittoux A, Peuskens J, Priori S, Sturkenboom M, Thomas SH, Tanghoj P, Toumi M, Mann R, Moore ND. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol 2010 20 829 38. [Pg.85]

Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 2008 10(7) 788-97. [Pg.118]

Akathisia has been related to suicidality and a study of first-episode patients with schizophrenia treated with haloperidol or risperidone found a positive relationship between suicidality and akathisia scores [45 ]. [Pg.62]

Susceptibility factors A study of 240 males with schizophrenia treated with haloperidol found statistically significant associations for dopaminergic type 2 receptor (DRD2) dopamine transporter (SLC6A3 VNTR) and catechol-O-methyltransferase gene polymorphisms and acute extrapyramidal symptoms [155. ... [Pg.68]

Seemuller F, Lewitzka U, Bauer M, Meyer S, MusQ R, Schennach R, et al. The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry 2012 45(7) 292-6. [Pg.77]

Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Tsuneyama N, et al. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. Schizophr Res 2013 145(l-3) 116-9. [Pg.78]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...